Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 11

The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders

Authors Levchenko A, Losenkov IS, Vyalova NM, Simutkin GG, Bokhan NA, Wilffert B, Loonen AJM, Ivanova SA

Received 17 April 2018

Accepted for publication 15 May 2018

Published 20 July 2018 Volume 2018:11 Pages 121—126

DOI https://doi.org/10.2147/PGPM.S171423

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Martin Bluth


Anastasia Levchenko,1,* Innokentiy S Losenkov,2,* Natalia M Vyalova,2 German G Simutkin,2 Nikolay A Bokhan,2,3 Bob Wilffert,4,5 Anton JM Loonen,4,6 Svetlana A Ivanova2,7

1Institute of Translational Biomedicine, Saint Petersburg State University, Saint Petersburg, Russia; 2Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russia; 3Department of Psychotherapy and Psychological Counseling, National Research Tomsk State University, Tomsk, Russia; 4Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherlands; 5University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; 6GGZ Westelijk Noord-Brabant, Bergen op Zoom, the Netherlands; 7Division for Control and Diagnostics, School of Non-Destructive Testing & Security, National Research Tomsk Polytechnic University, Tomsk, Russia

*These authors contributed equally to this work

Purpose: GSK3B and AKT1 genes have been implicated in the pathogenesis of a number of psychiatric and neurological disorders. Furthermore, their genetic variants are associated with response to antidepressant pharmacotherapy. As the evidence is still incomplete and inconsistent, continuing efforts to investigate the role of these two genes in the pathogenesis and treatment of brain disorders is necessary. The aim of our study was thus to evaluate the association of variants of these two genes with depressive disorders and drug treatment response.
Patients and methods: In the present study, 222 patients with a depressive disorder who underwent pharmacological antidepressant treatment were divided into remitters and non-remitters following a 28-day course of pharmacotherapy. The association of a depressive disorder and remission rates with polymorphisms rs334558 in the GSK3B gene and rs1130214 and rs3730358 in the AKT1 gene was evaluated with a chi-square test.
Results: Neither of the studied genetic variants was associated with a depressive disorder. Furthermore, frequencies of alleles and genotypes for rs1130214 and rs3730358 were not different in the groups of remitters and non-remitters. However, the activating allele T of the functional polymorphism rs334558 was significantly associated with remission, when all types of antidepressant drugs were included. This association continued as a trend when only patients taking selective serotonin reuptake inhibitors were considered.
Conclusion: The present study provides support that the functional polymorphism rs334558 of GSK3B may play a role as a useful genetic and pharmacogenetic biomarker in the framework of personalized medicine approach.

Keywords: depressive disorder, association study, AKT1, GSK3B, genetic biomarker

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]